Ivosidenib

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with ... acute myeloid leukemia (AML): ... myelodysplastic ...

Ivosidenib (oral route) - Mayo Clinic

Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older.

FDA approves ivosidenib for myelodysplastic syndromes

FDA approves ivosidenib for myelodysplastic syndromes.

Ivosidenib: MedlinePlus Drug Information

These symptoms may occur up to 3 months after starting treatment with ivosidenib. At the first sign that you are developing differentiation ...

Ivosidenib - NCI

Ivosidenib works by blocking an abnormal enzyme that some cancer cells with specific changes in the IDH-1 gene make.

Ivosidenib - Wikipedia

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. ... It is a ...

Ivosidenib - LiverTox - NCBI Bookshelf

Ivosidenib is an orally available small molecule inhibitor of mutated isocitrate dehydrogenase-1 that is used as an antineoplastic agent in ...

Tibsovo (ivosidenib) dosing, indications, interactions ... - Medscape

500 mg PO qDay. For patients without disease progression or unacceptable toxicity, continue for a minimum of 6 months to allow time for clinical response.

Ivosidenib Plus Chemotherapy to Treat AML with IDH1 Mutation - NCI

For some people with acute myeloid leukemia (AML) that has an IDH1 mutation, combining ivosidenib (Tibsovo) with azacitidine may be a new ...

Ivosidenib: Uses, Interactions, Mechanism of Action | DrugBank Online

Ivosidenib is an isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a ...

FDA approves ivosidenib for advanced or metastatic ...

Oncology (Cancer) FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ...

See full prescribing information for. TIBSOVO. TIBSOVO® (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018. WARNING: DIFFERENTIATION SYNDROME IN ...

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat population.

ivosidenib | CDA-AMC - Canada's Drug Agency

Details ... Manufacturer Requested Reimbursement Criteria1: Ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly ...

Ivosidenib in IDH1-mutant, chemotherapy-refractory ... - PubMed

This study shows the clinical benefit of targeting IDH1 mutations in advanced, IDH1-mutant cholangiocarcinoma.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With ...

Ivosidenib treatment resulted in numerically improved overall survival benefits vs placebo, despite a high rate of crossover.

FDA Approval Summary: Ivosidenib for Relapsed or Refractory ...

In AG120-C-001, ivosidenib 500 mg orally once daily led to a CR + CRh rate of 33% (95% CI, 26%–40%) with a median DOR of 8.2 months (95% CI, 5.6–12 months) in ...

Ivosidenib or enasidenib combined with intensive chemotherapy in ...

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

Ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.

Ivosidenib significantly reduces triazole levels in patients with acute ...

Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.